The North American Marijuana Index spiked on Wednesday, as U.S. pot stocks posted significant gains following President Trump’s signing of the “Right to Try Act.” The bill, which allows terminally ill patients access to experimental medications not yet approved by the Food and Drug Administration also applies to medical marijuana, due in part to clinical trials currently in process by the Multidisciplinary Association of Psychedelic Sciences (MAPS). The MAPS trial is exploring the use of cannabis in veterans with PTSD, and, according to reports, qualifies under the “Right to Try Act.”

“We will be saving — I don’t even want to say thousands, because I think it’s going to be much more, thousands and thousands, hundreds of thousands,” said President Trump at Wednesday’s bill signing ceremony, surrounded by patients who would be affected by the bill. “We’re going to be saving tremendous numbers of lives.”

The Index gained 4.58 points, or 1.83 percent, to close out the day at 255.22, with The United States Marijuana Index gaining 2.78 percent and The Canadian Marijuana Index falling 0.15 percent.

Whether or not the bill will affect a significant number of patients, or is another example of Trump’s excessive bombast is a question of some critics of the legislation. A New York Times report out Wednesday notes that state-level “Right to Try” legislation, in effect in more than three-dozen states, has shown minimal results at best. As one expert told The Times, it is doubtful that “hundreds of thousands” of lives would be saved by the law, making Trump’s boasts seem a bit far-fetched.

In fact, a similar program has been on the books since the 1970s, known as compassionate use, or expanded access. According to The Times, under the program, the FDA approves nearly

Read More Here...